# 5-Amino-1MQ Peptide

> 5-Amino-1MQ is an NNMT inhibitor that targets nicotinamide metabolism, NAD+ balance, energy expenditure, and fat-mass pathways.

Canonical: https://pepflow.app/peptides/5-amino-1mq/

The NNMT Blocker

A selective nicotinamide N-methyltransferase inhibitor, not a peptide, discussed for fat-mass and NAD+ metabolism because mouse studies link NNMT blockade with higher energy expenditure and lower adiposity.

Weight loss  Anti-aging

Tier D

Evidence Limited

Safety Limited Data

FDA status Not Approved

Last reviewed August 11, 2026 9 citations [How to read these labels](<https://pepflow.app/peptide-label-legend/>)

## What is 5-Amino-1MQ?

5-Amino-1MQ is a quinolinium-derived small molecule that inhibits nicotinamide N-methyltransferase, the enzyme that methylates nicotinamide and connects NAD+ metabolism with methyl-donor balance. It is grouped in peptide catalogs because it is sold in the same metabolic-optimization market, but chemically it is not a peptide.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>)

The biological rationale comes from NNMT work in adipose tissue. NNMT knockdown protected mice from diet-induced obesity, and 5-amino-1MQ reversed several high-fat-diet changes in mice by raising intracellular NAD+ and SAM and shifting adipocyte energy metabolism.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/24717514/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

The naming can be misleading because 5-Amino-1MQ appears in peptide-oriented catalogs even though it is a small molecule. 5-Amino-1MQ, 5-amino-1-methylquinolinium, and NNMT inhibitor labels should be read as chemistry and target names, not as proof that products are interchangeable.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

## What 5-Amino-1MQ is investigated for

5-Amino-1MQ evidence is grouped by practical use case and oral and injectable route context. Each use case separates confidence, human evidence, animal or mechanistic support, and the practical takeaway.

### ### Fat loss without appetite suppression Oral, Injectable 40% Preliminary

Fat-loss claims remain rodent-derived; the non-appetite mechanism is plausible but unvalidated in humans.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/24717514/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

#### Human evidence

No published human trial has tested 5-Amino-1MQ for body weight, waist circumference, adipose tissue, appetite, or cardiometabolic outcomes.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/24717514/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

#### Animal / mechanistic evidence

Diet-induced obese mouse studies reported lower body weight and white-adipose-tissue mass without reduced food intake after NNMT inhibition, including direct 5-amino-1MQ experiments.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/24717514/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

### ### NAD+ and cellular energy metabolism Oral 35% Preliminary

NNMT inhibition gives a credible metabolic pathway, but no human data show improved NAD+-related health outcomes or long-term safety.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>)

#### Human evidence

Human outcome studies have not shown that 5-Amino-1MQ improves NAD+-related health outcomes.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>)

#### Animal / mechanistic evidence

Mechanistic work links NNMT inhibition with higher intracellular NAD+ and SAM and changes in adipocyte energy handling.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>)

### ### Cholesterol and lipid markers Oral, Injectable 28% Limited

Cholesterol claims should be framed as a preclinical metabolic-marker signal, not established lipid management.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

#### Human evidence

No human lipid trial has tested whether 5-Amino-1MQ changes cholesterol, triglycerides, or cardiometabolic risk markers.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

#### Animal / mechanistic evidence

The 11-day diet-induced-obesity mouse experiment reported lower total cholesterol along with lower fat mass after direct 5-amino-1MQ treatment.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

## Evidence snapshot

### Overall confidence

Limited

32%

5-Amino-1MQ remains a preclinical metabolic candidate. Mouse NNMT-inhibition studies and a coherent target rationale support interest, but no human outcome, pharmacokinetic, or chronic-safety trial has established practical use.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/24717514/>)

Overall confidence is a page-level composite, not an average; it weighs evidence quality, route/molecule match, and practical limitations.

8%

### Human evidence

Insufficient

No published human trial establishes efficacy, dosing, pharmacokinetics, or chronic safety for 5-Amino-1MQ.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%225-Amino-1MQ%22&limit=1>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

32%

### Animal / preclinical

Limited

Mouse NNMT-inhibition studies are the strongest outcome evidence, with adiposity and energy-expenditure endpoints. That still leaves the evidence model-based for human use.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/24717514/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

44%

### Mechanism support

Preliminary

NNMT connects nicotinamide methylation, NAD+ availability, SAM balance, and adipocyte metabolism. The target is coherent, but clinical translation is unproven.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

## Forms & administration

5-Amino-1MQ is most commonly discussed as oral capsules in compounded-market protocols. Injectable evidence remains preclinical, so the vial template uses a conservative editable market-practice seed rather than presenting an established human dose.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>) [\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%225-Amino-1MQ%22&limit=1>)

Oral Injectable

## Dosing & protocols

These ranges are general reference points, not personal dosing instructions.

### Typical Range

Common oral protocols use 50-100 mg per dose. No human injectable dose has been established; 5 mg is used as a starting amount.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

### Frequency

Oral protocols are usually taken once daily.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

### Timing Considerations

Morning is the usual timing.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>)

### Cycle Length

Common cycles run 8-12 weeks.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

[Full 5-Amino-1MQ dosage guide](<https://pepflow.app/peptides/5-amino-1mq/dosage/>)

## What to expect

### Weeks 2-4

Oral metabolic use usually feels quiet at first; appetite, energy, GI comfort, weight trend, and waist changes are the recognizable early signals.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

### Weeks 8-12

Body-composition and metabolic-lab trends become easier to compare with diet, training, and medication changes over a full oral cycle.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/24717514/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

### After stopping

Weight, appetite, and lab markers may drift back toward baseline after the cycle because human durability and washout data are missing.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

## Safety profile

For oral or other research-market use, practical safety attention belongs on product identity, GI or neurologic tolerability, liver metabolism, and signals that chronic NNMT inhibition could affect broader methylation or cancer-related biology. Human pharmacokinetics and long-term exposure are still not characterized.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>)

### Cautions

- Cancer biology uncertainty[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)
- Unapproved product quality[\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### What we don't know

Human pharmacokinetics, active dose, accumulation, washout, and dose-response are not defined.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

## Who 5-Amino-1MQ is not for

Route-specific avoid and medical-review notes:

- **Pregnancy or breastfeeding**

  Avoid because human reproductive safety and developmental effects of NNMT modulation are unknown.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)
- **Active or recent cancer**

  Medical review is warranted because NNMT is discussed in cancer biology and chronic inhibition has not been studied in humans.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

## Drug & supplement interactions

Documented interactions are separated from theoretical or route-specific cautions.

### Theoretical interactions

- **NAD+ precursors**

  NMN or NR may amplify NAD-related pathway changes when paired with oral NNMT inhibition; this is a theoretical mechanism-and-dose gap.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>)
- **One-carbon or methylation pathway drugs**

  Methylation-pathway drugs or high-dose methyl donors could make SAM and nicotinamide effects harder to interpret with oral 5-Amino-1MQ; this is a theoretical pathway caution.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

## Pairing notes

### Commonly included in these stacks

[**NAD+ / MOTS-c / 5-Amino-1MQ** NAD+ / MOTS-c / 5-Amino-1MQ is a mitochondrial and metabolic stack concept built around cellular energy handling. Direct NAD+ provides the redox cofactor itself, MOTS-c targets mitochondrial stress-response signaling, and 5-Amino-1MQ targets NNMT-linked nicotinamide metabolism. NAD+ MOTS-c 5-Amino-1MQ](<https://pepflow.app/stacks/nad-mots-c-5-amino-1mq/>)

## Regulatory status

### United States

5-Amino-1MQ has no FDA-approved oral or injectable drug use as of 2026-06-21. Availability as a research chemical or compounded preparation does not create FDA review of safety, effectiveness, quality, or human-use claims.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%225-Amino-1MQ%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

| Route | FDA drug approval | 503A compounding |
| --- | --- | --- |
| Oral | Not Approved · As of 2026-06-21, 5-Amino-1MQ was not FDA-approved as an oral or injectable drug. Research-market or compounded availability does not equal FDA approval.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%225-Amino-1MQ%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) | Not Listed · As of 2026-06-21, 5-Amino-1MQ was not identified on FDA's reviewed 503A bulk-substance materials for oral or injectable compounding. Compounded preparations are still not FDA-approved drugs.[\[7\]](<https://www.fda.gov/media/94155/download>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) |
| Injectable | Not Approved · As of 2026-06-21, 5-Amino-1MQ was not FDA-approved as an oral or injectable drug. Research-market or compounded availability does not equal FDA approval.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%225-Amino-1MQ%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) | Not Listed · As of 2026-06-21, 5-Amino-1MQ was not identified on FDA's reviewed 503A bulk-substance materials for oral or injectable compounding. Compounded preparations are still not FDA-approved drugs.[\[7\]](<https://www.fda.gov/media/94155/download>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>) |

### Oral

FDA drug approval

Not Approved

As of 2026-06-21, 5-Amino-1MQ was not FDA-approved as an oral or injectable drug. Research-market or compounded availability does not equal FDA approval.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%225-Amino-1MQ%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

503A compounding

Not Listed

As of 2026-06-21, 5-Amino-1MQ was not identified on FDA's reviewed 503A bulk-substance materials for oral or injectable compounding. Compounded preparations are still not FDA-approved drugs.[\[7\]](<https://www.fda.gov/media/94155/download>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### Injectable

FDA drug approval

Not Approved

As of 2026-06-21, 5-Amino-1MQ was not FDA-approved as an oral or injectable drug. Research-market or compounded availability does not equal FDA approval.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%225-Amino-1MQ%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

503A compounding

Not Listed

As of 2026-06-21, 5-Amino-1MQ was not identified on FDA's reviewed 503A bulk-substance materials for oral or injectable compounding. Compounded preparations are still not FDA-approved drugs.[\[7\]](<https://www.fda.gov/media/94155/download>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

### International

EU/Europe, UK, Canada, and Australia should be checked by local product and claim; no approved therapeutic 5-Amino-1MQ product was found in the reviewed official sources.

### Sports & competition

WADA's 2026 Prohibited List does not specifically name 5-Amino-1MQ, but tested athletes should treat systemic use of a non-approved pharmacological substance as an S0 risk unless cleared through anti-doping review.[\[9\]](<https://ita.sport/resource/wada-2026-prohibited-list/>)

## How it works

5-Amino-1MQ is a small-molecule NNMT inhibitor, not a peptide hormone. NNMT converts nicotinamide into 1-methylnicotinamide and uses methyl-donor capacity; in fat-cell and mouse obesity models, lowering NNMT shifts adipose metabolism toward greater energy expenditure rather than appetite suppression.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>) [\[1\]](<https://pubmed.ncbi.nlm.nih.gov/24717514/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>)

The practical mechanism is still target-based, not outcome-proven in humans. Oral or injectable exposure has to reach the right tissues, inhibit NNMT selectively, and avoid chronic methylation or cancer-biology problems before mouse fat-loss biology can reliably support an adult human outcome claim.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>) [\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

## Research gaps & open questions

What the current literature has not yet settled about 5-Amino-1MQ:

01

Studies in people still need to show how much oral 5-Amino-1MQ reaches the bloodstream, how long it remains in the body, and which doses are both useful and tolerable.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

02

Blocking NNMT for months or years could affect the liver, metabolism, methylation chemistry, or cancer biology; long-term human studies have not tested those risks.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

03

Controlled human trials need to show whether it actually changes weight, body fat, waist size, appetite, blood sugar, and cholesterol—and whether any benefit lasts after stopping.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

## Common questions

### Is 5-Amino-1MQ actually a peptide?

No. It is a small-molecule NNMT inhibitor that is discussed alongside metabolic peptides because of how it is marketed and used in optimization settings.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

### Does 5-Amino-1MQ work for human fat loss?

Not proven. The fat-mass signal comes from mouse and NNMT-mechanism work, not randomized human weight-loss trials for oral or injectable use.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

### Is 5-Amino-1MQ FDA-approved?

No. 5-Amino-1MQ has no FDA-approved oral or injectable drug use as of 2026-06-21, and compounded versions remain separate from FDA approval.[\[6\]](<https://api.fda.gov/drug/drugsfda.json?search=%225-Amino-1MQ%22&limit=1>) [\[8\]](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)

## Myths & misconceptions

### Myth

5-Amino-1MQ is a peptide.

### Reality

It is not a peptide; it is a quinolinium-derived NNMT inhibitor.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

### Myth

No appetite suppression means no safety concerns.

### Reality

The lack of an appetite-suppression mechanism does not establish human safety, especially for chronic NNMT inhibition.[\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

## History & discovery

5-Amino-1MQ entered peptide-adjacent discussions through NNMT obesity biology rather than peptide discovery: researchers first linked adipose NNMT to energy metabolism, then used a small-molecule inhibitor to probe that target.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/24717514/>) [\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

Mouse knockdown work showed that reducing NNMT in white adipose tissue protected against diet-induced obesity, making the enzyme a plausible metabolic target.[\[1\]](<https://pubmed.ncbi.nlm.nih.gov/24717514/>)

A medicinal-chemistry paper described 5-amino-1MQ as a selective, membrane-permeable NNMT inhibitor and reported anti-obesity effects in high-fat-diet mice.[\[2\]](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)

Recent NNMT reviews shifted the discussion toward drug-development feasibility, while noting that human efficacy, dosing, and safety questions remain unresolved for inhibitors.[\[4\]](<https://pubmed.ncbi.nlm.nih.gov/39604638/>) [\[5\]](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)

## Published research 9 citations

- [\[1\] **Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity.** Nature, 2014 Apr 10. review.](<https://pubmed.ncbi.nlm.nih.gov/24717514/>)
- [\[2\] **Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high fat diet-induced obesity in mice.** Biochemical pharmacology, 2018 Jan. animal.](<https://pubmed.ncbi.nlm.nih.gov/29155147/>)
- [\[3\] **Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in DIO mice.** Scientific reports, 2022 Jan 10. animal.](<https://pubmed.ncbi.nlm.nih.gov/35013352/>)
- [\[4\] **Exploring NNMT: from metabolic pathways to therapeutic targets.** Archives of pharmacal research, 2024 Dec. review.](<https://pubmed.ncbi.nlm.nih.gov/39604638/>)
- [\[5\] **Emerging opportunities for nicotinamide N-methyltransferase (NNMT) inhibitor clinical translation.** Trends in pharmacological sciences, 2026 Jun. review.](<https://pubmed.ncbi.nlm.nih.gov/42067476/>)
- [\[6\] **Drugs@FDA/openFDA query for 5-Amino-1MQ** U.S. Food and Drug Administration / openFDA. database query.](<https://api.fda.gov/drug/drugsfda.json?search=%225-Amino-1MQ%22&limit=1>)
- [\[7\] **Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act** U.S. Food and Drug Administration, 2026-05-14. regulatory.](<https://www.fda.gov/media/94155/download>)
- [\[8\] **Compounding and the FDA: Questions and Answers** U.S. Food and Drug Administration. official guidance.](<https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers>)
- [\[9\] **The 2026 List of Prohibited Substances and Methods** World Anti-Doping Agency, 2026. regulatory.](<https://ita.sport/resource/wada-2026-prohibited-list/>)

[PepFlow library coverage](<https://pepflow.app/research/peptide-library/>)

## Quick facts

**Family**

Redox/NAD metabolism compound

**Tier**

D

**Evidence**

32% Limited

**Safety**

Limited Data

**FDA status**

Not Approved

**Oral 503A**

Not Listed

**Citations**

[9 citations](<https://pepflow.app/peptides/5-amino-1mq/#published-research>)

**Updated**

August 11, 2026

### Potential benefits

- Fat loss without appetite suppression
- NAD+ and cellular energy metabolism
- Cholesterol and lipid markers

### Also known as

- 5-Amino-1MQ
- 5-amino-1-methylquinolinium
- NNMT inhibitor
- 5-amino-1MQ chloride

## Related

- [Peptide Label Key](<https://pepflow.app/peptide-label-legend/>)
- [5-Amino-1MQ dosage guide](<https://pepflow.app/peptides/5-amino-1mq/dosage/>)
- [NAD+ / MOTS-c / 5-Amino-1MQ](<https://pepflow.app/stacks/nad-mots-c-5-amino-1mq/>)
- [PepFlow Library Statistics (2026) · 65 Profiles](<https://pepflow.app/research/peptide-library/>)
